Albany Molecular Research Net Income

Albany Molecular Research posts a net income of $-60M as of June 2017. That compares with $-34M in the prior-year period — down 77.3% year over year. That is below the sector sector average of $89M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Albany Molecular Research's net income was $-34M. The latest reading is $-60M — a 77.3% year-over-year decrease (period ending June 2017). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a net income near $89M is typical. Albany Molecular Research's $-60M is lower that level. That is roughly 167.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Albany Molecular Research's financial statement story. At $-60M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AMRI's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $89M), and (3) consistency with growth and profitability. This page covers the first two; Albany Molecular Research's other metric pages and overview cover the third.